FDA Approves AstraZeneca and Ionis' Wainua for Rare Nerve Disease

The self-administered drug, projected to match Alnylam's Amvuttra's annual price of $463,500, is also being tested for cardiomyopathy.

The FDA has approved Wainua, a drug developed by AstraZeneca and Ionis Pharmaceuticals, for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
Wainua is the only approved medicine for this condition that can be self-administered via an auto-injector.
Analysts predict peak sales of Wainua could reach over $700 million in the treatment of this condition alone.
The official list price for Wainua has not been disclosed, but it is anticipated to match Alnylam's Amvuttra at approximately $463,500 per year.
Ionis and AstraZeneca are also testing Wainua for other forms of the disease that can lead to cardiomyopathy.